OTCMKTS:CSLLY CSL (CSLLY) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free CSLLY Stock Alerts $95.05 -1.50 (-1.55%) (As of 06/7/2024 08:53 PM ET) Add Compare Share Share Today's Range$94.81▼$95.6750-Day Range$86.82▼$96.5552-Week Range$71.51▼$105.11Volume20,700 shsAverage Volume36,046 shsMarket Capitalization$91.87 billionP/E RatioN/ADividend Yield1.15%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get CSL alerts: Email Address Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About CSL Stock (OTCMKTS:CSLLY)CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More CSLLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSLLY Stock News HeadlinesMay 30, 2024 | prnewswire.comCSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian InfluenzaMay 29, 2024 | msn.comHow much passive income would a $10,000 investment in CSL shares generate?May 20, 2024 | prnewswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 20, 2024 | businesswire.comNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 19, 2024 | msn.comBMW M CEO Teases M4-Based 3.0 CSL HomageMay 16, 2024 | investorplace.comCSLR Stock Earnings: Complete Solaria Misses EPS, Misses Revenue for Q1 2024May 2, 2024 | markets.businessinsider.comCSL : Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza VaccinesMay 2, 2024 | prnewswire.comRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three SeasonsApril 28, 2024 | msn.comHere is the dividend forecast to 2028 for CSL sharesApril 25, 2024 | investorplace.comCSL Stock Earnings: Carlisle Companies Beats EPS, Beats Revenue for Q1 2024April 24, 2024 | prnewswire.comCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 16, 2024 | msn.comHow much do you need to invest in CSL shares for $8,000 in annual dividends?April 12, 2024 | markets.businessinsider.comUBS Sticks to Their Buy Rating for CSL (CMXHF)April 9, 2024 | afr.comMacquarie brokers say CSL is heading to $500 per shareApril 5, 2024 | investorplace.comCSLR Stock Earnings: Complete Solaria Beats EPS, Misses Revenue for Q4 2023April 2, 2024 | fool.com.auOwn CSL shares? You're receiving a healthy dividend boost today!March 28, 2024 | finance.yahoo.comVafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patientsMarch 26, 2024 | afr.comBlood giant CSL works up $US1 billion-plus bond deal; banks mandatedMarch 11, 2024 | finance.yahoo.comCSL Ltd's Dividend AnalysisMarch 6, 2024 | prnewswire.comCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. SeasonFebruary 15, 2024 | markets.businessinsider.comWilsons downgrades CSL (CMXHF) to a HoldFebruary 13, 2024 | fool.com.auCSL shares tumble despite first-half earnings beatFebruary 13, 2024 | afr.comWhat we learnt from CSL, Challenger, Seek and Breville’s resultsFebruary 13, 2024 | finanznachrichten.deCSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³February 12, 2024 | fool.com.auCSL share price on watch amid 20% profit jumpSee More Headlines Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/10/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees32,000Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio30.37 P/E Growth2.09Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$13.31 billion Price / Sales6.90 Cash Flow$3.14 per share Price / Cash Flow30.31 Book Value$18.48 per share Price / Book5.14Miscellaneous Outstanding Shares966,510,000Free FloatN/AMarket Cap$91.87 billion OptionableNot Optionable Beta0.77 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Paul F. McKenzie Ph.D. (Age 58)MD, CEO & Executive Director Comp: $2.75MMs. Joy Carolyn Linton B.Com. (Age 59)BComm, GAICD, Grad Dip AFI, Chief Financial Officer Comp: $2.05MMr. Mark DehringHead of Investor RelationsMr. Gregory Boss B.S. (Age 63)BS(Hons), J.D., Executive VP of Legal & General Counsel Comp: $1.1MChristina HickieSenior Manager of CommunicationsMs. Roanne ParryChief Human Resources OfficerDr. Karen Etchberger (Age 66)Executive Vice President of Quality & Business Services Comp: $1.03MMs. Jemimah BrennanHead of Communications - Asia PacificDr. Andrew D. Nash BSc (Hons) (Age 62)GAICD, Ph.D., Senior Vice President of Research Dr. William Mezzanotte M.D. (Age 65)M.P.H., Executive VP & Head of Research and Development Comp: $1.46MMore ExecutivesKey CompetitorsJohnson & JohnsonNYSE:JNJMerck & Co., Inc.NYSE:MRKAbbVieNYSE:ABBVAstraZenecaNASDAQ:AZNNovartisNYSE:NVSView All Competitors Should I Buy CSL Stock? CSLLY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in CSL Limited: CSL Limited has shown consistent revenue growth over the past few quarters, indicating a strong financial performance. The company has a solid track record of profitability, with a healthy return on equity and net margin, showcasing efficient operations. CSL Limited recently announced a dividend increase, providing investors with a steady income stream. Analysts project positive earnings per share for CSL Limited in the upcoming year, suggesting potential for stock price appreciation. The current stock price of CSL Limited is trading at a discount compared to its intrinsic value, presenting a buying opportunity for investors. Cons Investors should be bearish about investing in CSL Limited for these reasons: CSL Limited faces increasing competition in its industry, which could impact market share and profitability. The company's stock price is susceptible to market volatility, potentially leading to short-term fluctuations in value. CSL Limited's payout ratio is relatively high, indicating a significant portion of earnings is being distributed as dividends, limiting reinvestment for growth. Some analysts have issued downgrades on CSL Limited's stock, citing concerns about future growth prospects and valuation. Investors should carefully monitor any regulatory changes or legal issues that could affect CSL Limited's operations and financial performance. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 7, 2024. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com. CSLLY Stock Analysis - Frequently Asked Questions How have CSLLY shares performed in 2024? CSL's stock was trading at $97.17 at the start of the year. Since then, CSLLY stock has decreased by 2.2% and is now trading at $95.05. View the best growth stocks for 2024 here. Are investors shorting CSL? CSL saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 14,400 shares, an increase of 54.8% from the April 30th total of 9,300 shares. Based on an average daily trading volume, of 62,100 shares, the short-interest ratio is currently 0.2 days. View CSL's Short Interest. Is CSL a good dividend stock? CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.09 per share and currently has a dividend yield of 1.15%. Read our dividend analysis for CSLLY. How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CSLLY) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CSL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.